Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Truscreen GroupASX:TRU +7.69% 3-Year ROIIC % is 32.09 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Truscreen Group ranks better than 77.76% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Truscreen Group's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 32.09%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Truscreen Group's 3-Year ROIIC % or its related term are showing as below:
ASX:TRU's 3-Year ROIIC % is ranked better than 77.76% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs ASX:TRU: 32.09
Truscreen Group (ASX:TRU) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Truscreen Group 3-Year ROIIC % Related Terms
Truscreen Group 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Truscreen Group's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:TRU vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Truscreen Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Truscreen Group 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Truscreen Group's 3-Year ROIIC % falls into.
Truscreen Group's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -2.194 (Mar. 2026) - -2.736 (Mar. 2023) )
/
( 1.227 (Mar. 2026) - 0.475 (Mar. 2023) )
=
0.542
/
0.752
=
72.07%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Truscreen Group (ASX:TRU) has a 3-Year ROIIC % of 32.09 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Truscreen Group and its competitors. According to the industry distribution chart, Truscreen Group ranks #177 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 22.2%.
Is Truscreen Group's 3-Year ROIIC % too high?
Truscreen Group's current 3-Year ROIIC % is 32.09. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.62. Truscreen Group's value of 32.09 is 1880.9% above this industry median. Based on the distribution chart, Truscreen Group ranks #177 out of 796 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Truscreen Group's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Truscreen Group ranks #177 out of 796 companies for 3-Year ROIIC %. This places Truscreen Group in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.62. Truscreen Group's value of 32.09 is 1880.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.62, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Truscreen Group's current 3-Year ROIIC % of 32.09 is 1880.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Truscreen Group and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Truscreen Group's current 3-Year ROIIC % is 32.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (ASX:TRU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 40% above its estimated fair value. The current 3-Year ROIIC % is 32.09 and 1880.9% above the Medical Devices & Instruments industry median of 1.62. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Truscreen Group (ASX:TRU), the current 3-Year ROIIC % is 32.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRU has been successfully added to your 
